ArticleCancer medicine2026
Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A lactylation-related gene signature predicts prognosis and immunotherapy response in clear cell renal cell carcinoma based on machine learning and multi-omics analysis.Discover oncology · 2026Article
- Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBladder cancer remains a significant challenge in oncology owing to its high recurrence rates and limited treatment options, particularly in cases of resistance to standard therapies.
aimsOur study aimed to pinpoint a lactylation-associated gene signature capable of predicting prognosis and providing important theoretical support for drug development and precision therapy in bladder cancer patients. MATERIALS AND
methodsLeveraging RNA sequencing data from the TCGA and GEO databases, we scrutinized the expression profiles of lactylation-associated genes and pinpointed a signature comprising eight genes strongly linked to prognosis based on a machine learning integrative framework. Our prognostic model, incorporating the expression levels of these lactylation-associated genes, demonstrated high accuracy in predicting patient outcomes, including survival rates and response to immunotherapy. Furthermore, functional analyses revealed the potential mechanisms through which lactylation-associated genes contribute to bladder cancer progression and treatment resistance. Further validation of the close association of these eight genes with bladder cancer was also confirmed through in vitro RT-PCR experiments and Human Protein Atlas (HPA). The drug enrichment analysis and molecular docking provide us with potential drugs and their binding modes with target proteins. To further investigate the relationship between the model gene and bladder cancer, we conducted a series of in vitro experiments.
resultsWe found that knockdown of AHNAK reduced the proliferation, migration, and invasion abilities of bladder cancer cells and also promoted cell apoptosis. DISCUSSION: Overall, our study highlights the importance of lactylation-associated genes as prognostic markers and potential therapeutic targets in bladder cancer.
conclusionOur identification of this gene signature lays the groundwork for personalized treatment strategies and enhanced patient management in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.